These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31099653)

  • 1. Approaches to High-Risk Resected Stage II and III Melanoma.
    Yushak M; Mehnert J; Luke J; Poklepovic A
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e207-e211. PubMed ID: 31099653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?
    Indini A; Roila F; Grossi F; Massi D; Mandalà M
    Am J Clin Dermatol; 2021 Jul; 22(4):511-522. PubMed ID: 34036489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
    Eggermont AM
    Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant and neoadjuvant therapy.
    McKean MA; Amaria RN
    Cancer Treat Rev; 2018 Nov; 70():144-153. PubMed ID: 30195813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanoma trials that defined surgical management: Brief overview of current/upcoming adjuvant/neoadjuvant trials.
    Patel A; Skitzki J
    J Surg Oncol; 2022 Jan; 125(1):38-45. PubMed ID: 34897704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant Therapy for Melanoma.
    Wada-Ohno M; Ito T; Furue M
    Curr Treat Options Oncol; 2019 Jun; 20(8):63. PubMed ID: 31236710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?
    Grob JJ; Garbe C; Ascierto P; Larkin J; Dummer R; Schadendorf D
    Lancet Oncol; 2018 Dec; 19(12):e720-e725. PubMed ID: 30507438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical Options for the Adjuvant Treatment and Management of Pediatric Melanoma.
    Raef HS; Friedmann AM; Hawryluk EB
    Paediatr Drugs; 2019 Apr; 21(2):71-79. PubMed ID: 30924056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequencing of New and Old Therapies for Metastatic Melanoma.
    Ratterman M; Hallmeyer S; Richards J
    Curr Treat Options Oncol; 2016 Oct; 17(10):52. PubMed ID: 27515170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of adjuvant therapy in melanoma management.
    Barth A; Morton DL
    Cancer; 1995 Jan; 75(2 Suppl):726-34. PubMed ID: 7805001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The adjuvant treatment revolution for high-risk melanoma patients.
    Spagnolo F; Boutros A; Tanda E; Queirolo P
    Semin Cancer Biol; 2019 Dec; 59():283-289. PubMed ID: 31445219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant vemurafenib in resected, BRAF
    Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D;
    Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.
    Eggermont AMM; Dummer R
    Eur J Cancer; 2017 Nov; 86():101-105. PubMed ID: 28968566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma.
    Trinh VA; Zobniw C; Hwu WJ
    Expert Opin Drug Saf; 2017 Aug; 16(8):933-940. PubMed ID: 28627943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Dreno B; Thompson JF; Smithers BM; Santinami M; Jouary T; Gutzmer R; Levchenko E; Rutkowski P; Grob JJ; Korovin S; Drucis K; Grange F; Machet L; Hersey P; Krajsova I; Testori A; Conry R; Guillot B; Kruit WHJ; Demidov L; Thompson JA; Bondarenko I; Jaroszek J; Puig S; Cinat G; Hauschild A; Goeman JJ; van Houwelingen HC; Ulloa-Montoya F; Callegaro A; Dizier B; Spiessens B; Debois M; Brichard VG; Louahed J; Therasse P; Debruyne C; Kirkwood JM
    Lancet Oncol; 2018 Jul; 19(7):916-929. PubMed ID: 29908991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adjuvant adoptive immunotherapy in patients with stage III and resected stage IV melanoma: a pilot study].
    Verdecchia GM; Ridolfi L; Ridolfi R; Riccobon A; Bertagni A; Vagliasindi A; Petrini M; Stefanelli M; Milandri C; Amadori D
    Tumori; 2003; 89(4 Suppl):298-300. PubMed ID: 12903626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary Approaches to In-Transit Melanoma.
    Perone JA; Farrow N; Tyler DS; Beasley GM
    J Oncol Pract; 2018 May; 14(5):292-300. PubMed ID: 29746804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent advances in the adjuvant treatment of high-risk melanoma].
    Merat R
    Rev Med Suisse; 2019 Jan; 15(N° 632-633):34-37. PubMed ID: 30629365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
    Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
    Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of melanoma with immune checkpoints inhibitors].
    Lupu J; Hamann P; Routier É; Robert C
    Rev Prat; 2021 Apr; 71(4):380-383. PubMed ID: 34161002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.